These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26297114)

  • 1. Epitope characterization of an anti-PIVKA-II antibody and evaluation of a fully automated chemiluminescent immunoassay for PIVKA-II.
    Kinukawa H; Shirakawa T; Yoshimura T
    Clin Biochem; 2015 Nov; 48(16-17):1120-5. PubMed ID: 26297114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and evaluation of analytical performance of a fully automated chemiluminescent immunoassay for protein induced by vitamin K absence or antagonist II.
    Fujita K; Kinukawa H; Ohno K; Ito Y; Saegusa H; Yoshimura T
    Clin Biochem; 2015 Dec; 48(18):1330-6. PubMed ID: 26210849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. gamma-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin.
    Naraki T; Kohno N; Saito H; Fujimoto Y; Ohhira M; Morita T; Kohgo Y
    Biochim Biophys Acta; 2002 Apr; 1586(3):287-98. PubMed ID: 11997080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A quantitative analytical method for PIVKA-II using multiple reaction monitoring-mass spectrometry for early diagnosis of hepatocellular carcinoma.
    Sohn A; Kim H; Yu SJ; Yoon JH; Kim Y
    Anal Bioanal Chem; 2017 Apr; 409(11):2829-2838. PubMed ID: 28168546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical and Clinical Performance Evaluation of the Abbott Architect PIVKA Assay.
    Ko DH; Hyun J; Kim HS; Park MJ; Kim JS; Park JY; Shin DH; Cho HC
    Ann Clin Lab Sci; 2018 Jan; 48(1):75-80. PubMed ID: 29531000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal plasma prothrombin (PIVKA-II) levels in hepatocellular carcinoma.
    Kawaguchi Y
    Jpn J Surg; 1989 May; 19(3):296-300. PubMed ID: 2550692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of serum prothrombin induced by vitamin K absence or antagonist-II in the early detection of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
    Yoon YJ; Han KH; Kim DY
    Scand J Gastroenterol; 2009; 44(7):861-6. PubMed ID: 19391065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
    Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H
    Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
    Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
    Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific measurement of hypocarboxylated prothrombin in plasma or serum and application to the diagnosis of hepatocellular carcinoma.
    Grosley BM; Hirschauer C; Chambrette B; Bezeaud A; Amiral J
    J Lab Clin Med; 1996 Jun; 127(6):553-64. PubMed ID: 8648260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
    Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
    Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
    Fujiyama S; Morishita T; Shibata J; Sato T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.
    Svobodova S; Karlikova M; Topolcan O; Pecen L; Pestova M; Kott O; Treska V; Slouka D; Kucera R
    In Vivo; 2018; 32(6):1551-1554. PubMed ID: 30348715
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Des-gamma-carboxy prothrombin (DCP) ratio, a novel parameter measured by monoclonal antibodies MU-3 and 19B7, as a new prognostic indicator for hepatocellular carcinoma.
    Sugimoto H; Takeda S; Inoue S; Kaneko T; Watanabe K; Nakao A
    Liver Int; 2003 Feb; 23(1):38-44. PubMed ID: 12640726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of up-converting phosphor technology-based lateral flow assay for quantitative detection of serum PIVKA-II: Inception of a near-patient PIVKA-II detection tool.
    Huang Y; Zhang S; Zheng Q; Li Y; Yu L; Wu Q; Zheng J; Wu Y; Qiu F; Gao Q; Zhang J
    Clin Chim Acta; 2019 Jan; 488():202-208. PubMed ID: 30445030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of the heterogeneity of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma.
    Uehara S; Gotoh K; Handa H; Tomita H; Senshuu M
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1545-52. PubMed ID: 16174072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical usefulness of serum PIVKA-II levels determined by ECLIA system as a tumor maker for hepatocellular carcinoma].
    Sakizono K; Oita T; Shibata Y; Tamura A; Kasakura S
    Rinsho Byori; 1998 Sep; 46(9):936-41. PubMed ID: 9800480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
    Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
    Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of an enzyme immunoassay using monoclonal antibody (HG1-219) and its application for the diagnosis of hepatocellular carcinoma.
    Hada T; Kinoshita Y; Ichimori Y; Imanishi H; Umeyama K; Amuro Y; Toyosaka A; Okamoto E; Higashino K
    Jpn J Cancer Res; 1992 Dec; 83(12):1366-72. PubMed ID: 1282911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fully validated SRM-MS-based method for absolute quantification of PIVKA-II in human serum: Clinical applications for patients with HCC.
    Sohn A; Kim H; Yeo I; Kim Y; Son M; Yu SJ; Yoon JH; Kim Y
    J Pharm Biomed Anal; 2018 Jul; 156():142-146. PubMed ID: 29702392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.